-
A
12 Week, Double-Blind, Fixed Dose Comparison of 20 and 40
mg daily of Study Drug and Placebo in Patients Suffering from
Posttraumatic Stress Disorder (PTSD).
-
Placebo-Controlled
Study of the Safety and Efficacy of Study Drug in the Treatment
of Acute
Manic or Mixed Episodes in Subjects with Bipolar I Disorder.
-
Open-Label
Extension Study of the Safety and Tolerability of Study Drug
in Subjects with
Bipolar Disorderwho Completed Protocol Study Drug.
-
Study
Drug for the Treatment of Tardive Dyskinesia in Schizophrenic
Patients.
-
The
Combination of Study Drug and Study Drug in Treatment Resistant
Depression without
Psychotic Features.
-
A
Placebo-Controlled Study of Study Drug and Paroxetine in Patients
with Panic Disorder
-
Open-Label
Safety Study of Study Drug Patients with Anxiety Disorders
-
A
Randomized, Double-Blind, Placebo- and Risperidone-Controlled,
Multicenter Study to
Evaluate the Efficacy and Safety of Two Nonoverlapping Dose
Ranges of Study Drug given BID for 42 days to Schizophrenic
Patients with Acute or Subacute Exacerbation, Followed by
a Risperidone-Controlled, Long-Term Treatment Phase with Study
Drug given QD.
-
The
Comparative Efficacy of Study Drug, Risperidone, and Haloperidol
for Cognition in
Schizophrenia.
-
A
Multicenter, Randomized, Double-Blind, Placebo Controlled
Study of Three Fixed Doses of Study Drug in the Treatment
of Institutionalized Patients with Psychosis Associated with
Dementia of the Alzheimer's Type.
-
A
Double-Blind, Placebo-Controlled, 3-Arm Fixed Dose Study of
Study Drug Continuous
Treatment for Premenstrual Dysphoric Disorder.
